Please assess the completion status of the following clinical trial:

Trial Title: Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Patients with type 2 diabetes mellitus, diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled with basal insulin + SU (≤50% max allowed dose) ±1 oral antidiabetic (OAD) drug.~* Patients who express the intention to fast during Ramadan.~* Signed informed consent.~Exclusion criteria:~* At the time of screening age \< legal age of majority.~* Glycated hemoglobin (HbA1c) at screening visit: \<7.5% or \>10%.~* Body mass index (BMI) \<20kg/m\^2.~* Treatment with basal insulin for less than 6 months prior to screening.~* Prior antidiabetic medication (basal insulin and OADs) not at stable dose (eg, same medication, frequency and \<20% dose change) in the last 8 weeks prior to screening.~* Previous treatment with short or rapid acting insulin other than for short term use (≤10 days) in relation to hospitalization or an acute illness in the last 6 months prior to screening.~* Any discontinuation from a glucagon like peptide-1 receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.~* Patient not willing to perform self-monitored plasma glucose (SMPG) as required by protocol and to follow the instructions provided.~* Type 1, gestational or secondary diabetes.~* History of diabetic ketoacidosis.~* History of hypoglycemia unawareness.~* Any medical contraindication for sustained and safe fasting.~* Pregnant or breast-feeding women.~* Women of childbearing potential (WOCB) not protected by highly effective contraceptive method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy.~* Known hypersensitivity/intolerance to lixisenatide (Lyxumia) or any of its excipients.~* All contraindications of the comparator and protocol mandated background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lyxumia (Type: EXPERIMENTAL): Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete